Semin intervent Radiol 2022; 39(06): 571-576
DOI: 10.1055/s-0042-1759733
Review Article

The State of Evidence in Prostate Artery Embolization

Zahi Qamhawi
1   University Department of Radiology, Royal Berkshire Hospital, Reading, United Kingdom
,
Mark W. Little
1   University Department of Radiology, Royal Berkshire Hospital, Reading, United Kingdom
› Author Affiliations

Abstract

Prostate artery embolization (PAE) has emerged over the past two decades as a minimally invasive, nonsurgical treatment for benign prostatic hypertrophy (BPH). While the majority of evidence for PAE stems from retrospective cohort studies, several seminal randomized controlled trials have been performed comparing short-term outcomes of PAE to transurethral resection of prostate (TURP) and against a sham procedure. Across clinical trials, PAE demonstrates consistent improvement in urological symptoms and quality of life in patients with BPH with low complication rates. When compared to TURP, the results are comparable, but there is a trend for better outcomes in certain clinical parameters with TURP. PAE is a suitable option for patients who are not surgical candidates, prefer nonsurgical treatment with an earlier return to routine activities, and wish to better preserve sexual function.



Publication History

Article published online:
20 December 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am 2016; 43 (03) 289-297
  • 2 Bortnick E, Brown C, Simma-Chiang V, Kaplan SA. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Ther Adv Urol 2020; 12: 1756287220929486
  • 3 Sagen E, Namnuan R-O, Hedelin H, Nelzén O, Peeker R. The morbidity associated with a TURP procedure in routine clinical practice, as graded by the modified Clavien-Dindo system. Scand J Urol 2019; 53 (04) 240-245
  • 4 Sun F, Crisóstomo V, Báez-Díaz C, Sánchez FM. Prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH): part 2, insights into the technical rationale. Cardiovasc Intervent Radiol 2016; 39 (02) 161-169
  • 5 Wu X, Zhou A, Heller M, Kohlbrenner R. Prostatic artery embolization versus transurethral resection of the prostate for benign prostatic hyperplasia: a cost-effectiveness analysis. J Vasc Interv Radiol 2022; S1051-0443 (22)01127-7
  • 6 Rink JS, Froelich MF, McWilliams JP. et al. Prostatic artery embolization for treatment of lower urinary tract symptoms: a Markov model-based cost-effectiveness analysis. J Am Coll Radiol 2022; 19 (06) 733-743
  • 7 DeMeritt JS, Elmasri FF, Esposito MP, Rosenberg GS. Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization. J Vasc Interv Radiol 2000; 11 (06) 767-770
  • 8 Amouyal G, Thiounn N, Pellerin O. et al. Clinical results after prostatic artery embolization using the PErFecTED technique: a single-center study. Cardiovasc Intervent Radiol 2016; 39 (03) 367-375
  • 9 Bagla S, Martin CP, van Breda A. et al. Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 2014; 25 (01) 47-52
  • 10 Grosso M, Balderi A, Arnò M. et al. Prostatic artery embolization in benign prostatic hyperplasia: preliminary results in 13 patients. Radiol Med (Torino) 2015; 120 (04) 361-368
  • 11 Kurbatov D, Russo GI, Lepetukhin A. et al. Prostatic artery embolization for prostate volume greater than 80 cm3: results from a single-center prospective study. Urology 2014; 84 (02) 400-404
  • 12 Qiu Z, Zhang C, Wang X. et al. Clinical evaluation of embolization of the superior vesical prostatic artery for treatment of benign prostatic hyperplasia: a single-center retrospective study. Wideochir Inne Tech Malo Inwazyjne 2017; 12 (04) 409-416
  • 13 Rampoldi A, Barbosa F, Secco S. et al. Prostatic artery embolization as an alternative to indwelling bladder catheterization to manage benign prostatic hyperplasia in poor surgical candidates. Cardiovasc Intervent Radiol 2017; 40 (04) 530-536
  • 14 Ray AF, Powell J, Speakman MJ. et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int 2018; 122 (02) 270-282
  • 15 Wang M, Guo L, Duan F. et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms as a result of large benign prostatic hyperplasia: a prospective single-center investigation. Int J Urol 2015; 22 (08) 766-772
  • 16 Yu SCH, Cho CCM, Hung EHY, Chiu PKF, Yee CH, Ng CF. Prostate artery embolization for complete urinary outflow obstruction due to benign prostatic hypertrophy. Cardiovasc Intervent Radiol 2017; 40 (01) 33-40
  • 17 Pisco JM, Bilhim T, Pinheiro LC. et al. Medium-and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol 2016; 27 (08) 1115-1122
  • 18 Bilhim T, Costa NV, Torres D, Pinheiro LC, Spaepen E. Long-term outcome of prostatic artery embolization for patients with benign prostatic hyperplasia: single-centre retrospective study in 1072 patients over a 10-year period. Cardiovasc Intervent Radiol 2022; 45 (09) 1324-1336
  • 19 Gao YA, Huang Y, Zhang R. et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate – a prospective, randomized, and controlled clinical trial. Radiology 2014; 270 (03) 920-928
  • 20 Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M. Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic-controlled analysis. Cardiovasc Intervent Radiol 2016; 39 (01) 44-52
  • 21 Radwan A, Farouk A, Higazy A, Samir YR, Tawfeek AM, Gamal MA. Prostatic artery embolization versus transurethral resection of the prostate in management of benign prostatic hyperplasia. Prostate Int 2020; 8 (03) 130-133
  • 22 Insausti I, Sáez de Ocáriz A, Galbete A. et al. Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 2020; 31 (06) 882-890
  • 23 Abt D, Hechelhammer L, Müllhaupt G. et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ 2018; 361: k2338
  • 24 Zhu C, Lin W, Huang Z, Cai J. Prostate artery embolization and transurethral resection of prostate for benign prostatic hyperplasia: a prospective randomized controlled trial. Zhongguo Jieru Yingxiang Yu Zhiliaoxue 2018; 12: 134-138
  • 25 Pisco JM, Bilhim T, Costa NV. et al. Randomised clinical trial of prostatic artery embolisation versus a sham procedure for benign prostatic hyperplasia. Eur Urol 2020; 77 (03) 354-362
  • 26 Zumstein V, Betschart P, Vetterlein MW. et al. Prostatic artery embolization versus standard surgical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol Focus 2019; 5 (06) 1091-1100
  • 27 Xu XJ, Li J, Huang XZ, Liu Q. An updated meta-analysis of prostatic arterial embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. World J Urol 2020; 38 (10) 2455-2468
  • 28 Xu Z, Zhou Z, Mu Y, Cai T, Gao Z, Liu L. An updated meta-analysis of the efficacy and safety of prostatic artery embolization vs. transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. Front Surg 2021; 8: 779571
  • 29 Jung JH, McCutcheon KA, Borofsky M. et al. Prostatic arterial embolisation for men with benign prostatic hyperplasia: a Cochrane review. BJU Int 2022; DOI: 10.1111/bju.15823.
  • 30 Russo GI, Kurbatov D, Sansalone S. et al. Prostatic arterial embolization vs open prostatectomy: a 1-year matched-pair analysis of functional outcomes and morbidities. Urology 2015; 86 (02) 343-348
  • 31 Michalak J, Tzou D, Funk J. HoLEP: the gold standard for the surgical management of BPH in the 21(st) century. Am J Clin Exp Urol 2015; 3 (01) 36-42
  • 32 Jones P, Rai BP, Aboumarzouk O, Somani BK. UroLift: a new minimally-invasive treatment for benign prostatic hyperplasia. Ther Adv Urol 2016; 8 (06) 372-376